Transgenic Nonhuman Animal (e.g., Mollusks, Etc.) Patents (Class 800/13)
-
Publication number: 20140096274Abstract: The present invention relates to variants of TNF family ligands which have been mutated at the ligand trimerisation interface so that they are not capable of assembling into trimers, and either assemble into dimers or remain as monomers. Such ligands bind to the TNF receptor but are unable to activate it, effectively functioning as competitive inhibitors. The invention also relates to nucleic acids encoding the variants of TNF family ligands, vectors and host cells comprising the nucleic acid and methods for the treatment of diseases associated with aberrant signalling through a TNF receptor.Type: ApplicationFiled: December 23, 2011Publication date: April 3, 2014Inventors: Wilhelmus Johannes Quax, Vicente R. Tur, Luis Serrano, Albert Martinus Van Der Sloot, Robbert H. Cool, Aart H.G. Van Assen
-
Publication number: 20140082757Abstract: The present invention relates to a method for preparing a transformed Caenorhabditis elegans (C. elegans) which reacts to glucose by exhibiting fluorescence, and to a method for screening for a candidate substance and for a novel gene capable of regulating glucose metabolism and metabolic diseases using the transformed Caenorhabditis elegans. The transformed Caenorhabditis elegans of the present invention is prepared such that changes in glucose may be easily observed on a real-time basis using a fluorescent microscope. The transformed Caenorhabditis elegans of the present invention enables substances for regulating glucose metabolism to be quickly and accurately discovered, and further, may be expected to significantly contribute to studies on a variety of incurable metabolism-related diseases such as obesity, diabetes, and the like.Type: ApplicationFiled: May 24, 2012Publication date: March 20, 2014Applicant: POSTECH ACADEMY INDUSTRY FOUNDATIONInventors: Seung Jae Lee, Dong Yeop Lee
-
Publication number: 20140068795Abstract: The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.Type: ApplicationFiled: August 2, 2013Publication date: March 6, 2014Inventors: Jean-Marie BUERSTEDDE, Hiroshi ARAKAWA
-
Publication number: 20140068796Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.Type: ApplicationFiled: October 18, 2013Publication date: March 6, 2014Applicant: CRYSTAL BIOSCIENCE, INC.Inventors: William Don Harriman, Robert Etches, Phil Leighton
-
Publication number: 20140068797Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: ApplicationFiled: March 15, 2013Publication date: March 6, 2014Applicants: UNIVERSITY OF VIENNA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jennifer A. Doudna, Martin Jinek, Emmanuelle Charpentier, Krzysztof Chylinski, James Harrison Doudna Cate, Wendell Lim, Lei Qi
-
Patent number: 8664471Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: GrantFiled: May 11, 2004Date of Patent: March 4, 2014Assignees: The University of Chicago, The University of WashingtonInventors: Brooke Bevis, Benjamin Glick
-
Patent number: 8658133Abstract: Methods and compositions relating to Alzheimer's disease are provided, including proteins that are differentially expressed in Alzheimer's disease as compared to the normal state. Further provided are methods, particularly experimental paradigms, for the identification of differential expressed proteins that are potential molecular targets for compounds to treat or prevent Alzheimer's disease. Also provided are methods for the identification and therapeutic use of compounds for the prevention and treatment of Alzheimer's disease.Type: GrantFiled: August 26, 2005Date of Patent: February 25, 2014Assignee: Proteome Sciences plcInventors: Malcolm Ward, Vaksha Patel, Emma McGregor, Nicola Leeds, Helen Byers, James Campbell, Kit-Yi Leung, Jules Westbrook
-
Publication number: 20140053287Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.Type: ApplicationFiled: August 14, 2013Publication date: February 20, 2014Applicant: VERENIUM CORPORATIONInventors: David P. WEINER, Lishan ZHAO, Peter LUGINBUHL, Ellen BURKE, Toby H. RICHARDSON, Paula M. HICKS
-
Publication number: 20140047571Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: October 11, 2013Publication date: February 13, 2014Applicant: Novozymes A/SInventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
-
Publication number: 20140030253Abstract: Humanized forms of murine GHR106 monoclonal antibodies and methods of using them are described. Humanized GHR106 monoclonal antibodies have high affinity and specificity to the corresponding tumor-associated antigen, gonadotropin-releasing hormone (GnRH) receptor comparable to murine GHR106.Type: ApplicationFiled: March 12, 2013Publication date: January 30, 2014Inventor: Gregory LEE
-
Patent number: 8629317Abstract: The invention relates to a non-human transgenic mammal with an IgH locus modified by replacement of the switching sequence S? with all or part of a transgene comprising the gene C? of a class A human immunoglobulin, including at least the exon, coding for the CH3 domain and the membrane exon and the applications of the above for the production of humanized class IgA antibodies.Type: GrantFiled: October 21, 2004Date of Patent: January 14, 2014Assignees: Centre National de la Recherche Scientifique, Universite de LimogesInventors: Michel Cogne, Christophe Sirac, Micael Bardel, Catherine Decourt, Caroline Le Morvan
-
Publication number: 20140013456Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided.Type: ApplicationFiled: September 18, 2013Publication date: January 9, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20140004129Abstract: Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.Type: ApplicationFiled: October 2, 2012Publication date: January 2, 2014Applicants: AMGEN CANADA INC., AMGEN INC.Inventors: Steven K Yoshinaga, Tak W. Mak, Arda Shahinian, Anna Trafuri Bladt, Giorgio Senaldi
-
Publication number: 20130345143Abstract: Provided are methods, compositions, and kits employing a molecule that exhibits a function of the PB1 domain. In particular, such methods, compositions, and kits may be used for inhibiting tumorigenesis. Also provided are molecules that exhibit a function of the PB1 domain and methods for making such molecules. Additionally provided are cell lines that express a polypeptide having a function of the PB1 domain, as well as transgenic animals that express a polypeptide having a function of the PB1 domain.Type: ApplicationFiled: January 31, 2013Publication date: December 26, 2013Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventor: Rutgers, The State University of New Jersey
-
Publication number: 20130345401Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.Type: ApplicationFiled: March 2, 2012Publication date: December 26, 2013Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Satoshi Sekiguchi, Manabu Takahisa, Masahiro Tomita
-
Publication number: 20130340102Abstract: Provided herein are humanized forms of murine RP215 monoclonal antibodies and methods of using the same. These humanized RP215 monoclonal antibodies were characterized in terms of their respective affinity and specificity to the corresponding tumor-associated antigen, CA215, and shown to be comparable to those of murine RP215.Type: ApplicationFiled: March 12, 2013Publication date: December 19, 2013Inventor: Gregory LEE
-
Publication number: 20130340103Abstract: The present invention relates to polynucleotides from Ostreococcus lucimarinus which code for desaturases and elongases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides, and to the polypeptides encoded by the polynucleotides. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Applicant: BASF Plant Science GmbHInventors: Jörg Bauer, Tom Wetjen
-
Publication number: 20130333059Abstract: The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject.Type: ApplicationFiled: September 26, 2012Publication date: December 12, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Saraswati Sukumar, Zhu Tao, Xinyan Wu, Hexin Chen
-
LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING MUTATIONS IN TWO FUNCTIONAL SUBDOMAINS AND USE THEREOF
Publication number: 20130326644Abstract: A LAGLIDADG homing endonuclease variant, having mutations in two separate subdomains, each binding a distinct part of a modified DNA target half-site, said LAGLIDADG homing endonuclease variant being able to cleave a chimeric DNA target sequence comprising the nucleotides bound by each subdomain. Use of said herodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy.Type: ApplicationFiled: June 13, 2013Publication date: December 5, 2013Applicant: CELLECTIS, S.A.Inventor: Frederic PAQUES -
Patent number: 8598409Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: GrantFiled: August 24, 2007Date of Patent: December 3, 2013Assignee: Intrexon CorporationInventors: Marianna Zinovievna Kapitskaya, Subba Reddy Palli
-
Publication number: 20130317569Abstract: Provided herein are compositions and methods for disrupting at least one reward-related behavior in an individual through the use of light-responsive opsin proteins used to control the polarization state of the cholinergic interneurons of the nucleus accumbens or the striatum.Type: ApplicationFiled: November 4, 2011Publication date: November 28, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Karl Deisseroth, Ilana Witten
-
Patent number: 8592644Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.Type: GrantFiled: August 11, 2010Date of Patent: November 26, 2013Assignee: Crystal Bioscience Inc.Inventors: William Don Harriman, Robert Etches, Phil Leighton
-
Publication number: 20130312127Abstract: Methods of disrupting germ cell migration and development in a fish embryo by inducing targeted expression of Sdf-1 a or Lif and disruption of the Sdf-1 a gradient or a Lif signaling pathway in the fish embryo have been developed. Plasmid constructs containing a gene encoding Sdf-1 a or Lif and a gene encoding a signaling sequence for targeted expression of Sdf-1 a or Lif have been generated. The plasmids will be administered to a fish or a population of fish to reproductively sterilize the population with efficacy of up to 100%. Transgenic fish of this invention are reproductively incompetent of genetically contaminating a wild fish population.Type: ApplicationFiled: December 2, 2011Publication date: November 21, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: Ten-Tsao Wong, Paul Collodi
-
Patent number: 8586363Abstract: Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.Type: GrantFiled: December 10, 2010Date of Patent: November 19, 2013Assignees: Regents of the University of Minnesota, Iowa State University Research Foundation, Inc.Inventors: Daniel F. Voytas, Adam Bogdanove, Feng Zhang, Michelle Christian, Tomas Cermak, Clarice Lauer Schmidt, Erin Doyle, Li Wang
-
Patent number: 8581023Abstract: The present invention relates to the method and use of fluorescent proteins in making purple transgenic fluorescent fish. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.Type: GrantFiled: July 30, 2012Date of Patent: November 12, 2013Assignee: Yorktown Technologies, L.P.Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
-
Patent number: 8581024Abstract: The present invention relates to transgenic blue ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.Type: GrantFiled: July 30, 2012Date of Patent: November 12, 2013Assignee: Yorktown Technologies, L.P.Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
-
Patent number: 8581025Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.Type: GrantFiled: October 29, 2012Date of Patent: November 12, 2013Assignee: Yorktown Technologies, L.P.Inventors: Alan Blake, Richard Crockett, Jeffrey Essner, Perry Hackett, Aidas Nasevicius
-
Publication number: 20130298267Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: July 19, 2013Publication date: November 7, 2013Inventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
-
Publication number: 20130298265Abstract: The present invention relates to methods of assembling a plurality of genetic units to form synthetic genetic constructs. This method involves appending universal adapter oligonucleotides and flexible adapter oligonucleotides to the 5? and 3? ends of separate genetic units to be assembled to form separate dual extended genetic units. The dual extended genetic units are assembled together via homologous recombination between the flexible adapter oligonucleotide portions of the dual extended units to form synthetic genetic constructs. The present invention further relates to synthetic genetic constructs formed using the methods of the present invention, and vectors, cells, and organisms containing such synthetic genetic constructs.Type: ApplicationFiled: October 12, 2011Publication date: November 7, 2013Applicant: CORNELL UNIVERSITYInventors: Sébastien Cunnac, Alan Collmer
-
Publication number: 20130298264Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.Type: ApplicationFiled: April 19, 2013Publication date: November 7, 2013Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice
-
Publication number: 20130298268Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.Type: ApplicationFiled: July 16, 2013Publication date: November 7, 2013Inventor: JAMES WEST
-
Publication number: 20130298266Abstract: The invention relates to a non-human multicellular organism carrying a dominant lethal genetic system, the lethal effect of which is conditional, wherein the lethal effect of the lethal system occurs in the natural environment of the organism.Type: ApplicationFiled: July 15, 2013Publication date: November 7, 2013Inventors: Luke ALPHEY, Dean THOMAS
-
Publication number: 20130298263Abstract: The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Inventors: Takao Iwawaki, Daisuke Oikawa
-
Publication number: 20130291136Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
-
Publication number: 20130291132Abstract: The present invention relates to transgenic animals comprising a mutation or deletion to the ANF-RGC protein, particularly to its ARM and/or its ATS-ST region. Such animals may be used to study the effects on pathways associated with ANF-RGC activation, including, but not limited to, hypertension. Such animals may also be used in drug screen assays, to establish toxicity profiles, or other similar methods discussed herein known in the art.Type: ApplicationFiled: May 21, 2012Publication date: October 31, 2013Applicant: SALUS UNIVERSITYInventors: Rameshwar K. Sharma, Teresa Duda
-
Publication number: 20130276156Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.Type: ApplicationFiled: September 13, 2012Publication date: October 17, 2013Applicant: Intrexon CorporationInventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
-
Publication number: 20130276155Abstract: A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera Atrax and Hadronyche have been described. Also included are polynucleotides and expression vectors encoding the polypeptides and insect viruses and cells expressing the polypeptides. Transgenic plants and insects expressing the insecticidal polypeptides are also described. The insecticidal polypeptides may be employed in methods and compositions for treating insects, insect larvae, and plants.Type: ApplicationFiled: September 28, 2012Publication date: October 17, 2013Applicants: University of Technology, Sydney, University of ConnecticutInventors: University of Connecticut, University of Technology, Sydney
-
Publication number: 20130273021Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: March 11, 2011Publication date: October 17, 2013Applicant: SYNAGEVA BIOPHARMA CORP.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Patent number: 8558055Abstract: The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFN?, TNF-?, IL-2, IL-10, and IL-12.Type: GrantFiled: July 23, 2010Date of Patent: October 15, 2013Assignee: Transposagen Biopharmaceuticals, Inc.Inventors: Eric M. Ostertag, John Stuart Crawford
-
Publication number: 20130267682Abstract: To provide a new natural fiber material with excellent physical properties. Any one of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence of SEQ ID NO: 1 or 19; (b) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2 or 20; (c) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (a); (d) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (a) under stringent conditions.Type: ApplicationFiled: June 18, 2013Publication date: October 10, 2013Inventors: Tianfu ZHAO, Yujun WANG, Masao NAKAGAKI
-
Publication number: 20130263292Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 29, 2012Publication date: October 3, 2013Applicant: Kymab LimitedInventors: Qi Liang, Allan Bradley, E-Chiang Lee, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Publication number: 20130254908Abstract: MO-1 is a newly identified gene and gene product associated with morbid obesity. Isolated MO-1 nucleic acids, MO-1 polypeptides, oligonucleotides that hybridize to MO-1 nucleic acids, and vectors, including expression vectors, comprising MO-1 nucleic acids are disclosed, as are isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to MO-1. Methods of detecting the presence of MO-1 nucleic acid, methods of screening for agents which affect MO-1 activity, and methods of screening for MO-1 variants are also disclosed.Type: ApplicationFiled: October 12, 2012Publication date: September 26, 2013Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Adel Shalata, John Martignetti, Robert Desnick
-
Publication number: 20130252339Abstract: The invention relates to isolated nucleic acids comprising mir-302 genes. Also disclosed are expression vectors, host cells, and transgenic animals containing the nucleic acids, and use of the nucleic acids to generate ES-like cells.Type: ApplicationFiled: February 25, 2013Publication date: September 26, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Shi-Lung LIN, Shao-Yao YING
-
Publication number: 20130254909Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.Type: ApplicationFiled: March 4, 2013Publication date: September 26, 2013Applicant: Duke UniversityInventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
-
Patent number: 8541646Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.Type: GrantFiled: October 4, 2010Date of Patent: September 24, 2013Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in BiomedicineInventors: Sean Stevens, Andrew J. Murphy, Richard Flavell, Elizabeth Eynon, Jorge Galan, Tim Willinger, Markus Manz, Anthony Rongvaux, George D. Yancopoulos
-
Publication number: 20130247236Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Publication number: 20130247234Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20130247232Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.Type: ApplicationFiled: September 23, 2011Publication date: September 19, 2013Applicant: NEOGENIX ONCOLOGY, INC.Inventor: Xue-Ping Wang
-
Publication number: 20130243751Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: September 19, 2013Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
-
Publication number: 20130243759Abstract: The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous antibody chain expression has been inactivated.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: KYMAB LTD.Inventors: Glenn A. Friedrich, E-Chiang Lee